NEW YORK (GenomeWeb News) - Utrecht University will use GeneGo’s MetaDrug software and database platform in its master’s program for drug innovation, GeneGo said today.
MetaDrug is designed to predict human metabolism, toxicity, and biological effects of small-molecule compounds.
"Academia pushes the limits of MetaDrug,” said Julie Bryant, GeneGo’s vice president of business development, in a statement, because it “allows us to further adapt it for new areas of medicinal chemistry.”
Financial terms of the agreement were not released.